Denver is now a buyer's market for housing
By the numbers: A Zillow analysis found 38% of real estate listings in the metro area reduced their prices, well above the national average of almost 27%. Both numbers set new records for the month.
What they're saying: "The gap between buyers and sellers is shrinking. This is a healthy rebalancing," wrote Zillow senior economist Orphe Divounguy.
The big picture: The shifting landscape comes after years of bidding wars and elevated prices in a period of significant growth during the COVID-19 pandemic.
Denver is one of only a handful of metro areas where the housing inventory surpassed the national average.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
34 minutes ago
- Chicago Tribune
Illinois' rental assistance program has restarted. Here's what you need to know.
Struggling to pay your rent? Need to get paid for rent you are owed? There's a solution for those issues again after a two-month hiatus: Illinois' court-based rental assistance program reopened on July 31. While the program saw a third of its funds wiped away for the 2026 fiscal year that began July 1, $50 million in state funds are available. The reduction came as rents in Chicago keep rising and after the state grappled with serious fiscal challenges when balancing its budget this year, issues exacerbated by a federal government focused on axing spending. State lawmakers cut spending in various areas beyond housing as well. The state rental assistance program was previously funded by federal aid distributed during the COVID-19 pandemic and focused on helping tenants experiencing COVID-19-related hardships and at risk of eviction. The program has helped tens of thousands of renters and landlords since its inception in 2020. In the 2025 fiscal year, the inaugural year as a state-funded effort, more than $63 million in aid was distributed to help more than 7,680 families facing eviction. Around 39% of aided households were extremely low income, earning less than $36,000 a year for a household of four, the state said. The need was greater than the Illinois Housing Development Authority, the group in charge of administering the funds, expected, the agency said, which is why the program closed about three weeks before the end of the last fiscal year. Eviction filings in Cook County have hovered around pre-pandemic levels since 2022. Here's what you need to know about the state's court-based rental assistance program: Eligible tenants have to make 80% or less of the area median income and do not have to be facing a COVID-19-related hardship. For a household of four in Chicago, the income eligibility threshold is $95,900 or less, according to the Chicago Department of Housing's area median income calculations. For this year's round of assistance, the state said tenants will be ineligible if they have received aid in the last 18 months. Renters do not have to prove their citizenship status and must have an active eviction case due to nonpayment of rent to qualify. Housing providers are not allowed to evict tenants during the grant's coverage period for nonpayment of rent. For tenants whose landlords are unwilling to participate in the program, the state offers up to two months of future rent payments to help them find a new place to live. Renters in Chicago and Cook County maintain the right to stay in their homes if they pay their debts in full to their landlord at any time before an official eviction order is filed. Tenants and landlords can receive up to $10,000 in rental assistance per eviction case. This is a reduction from last year's $15,000 ceiling when the program was better funded. Kristin Faust, the Illinois Housing Development Authority's executive director, previously told the Tribune this decision was made based on data from last year's program and conversations with legal aid, tenants and landlords. The average grant amount last year was around $8,300, or eight months of rent. The authority estimates about 6,500 households will be able to receive assistance this year. The money can go toward paying past-due rent, up to $700 in court costs — up from $500 last year — and up to two months of future rent. To apply for the Illinois Court-Based Rental Assistance Program, go to The court-based rental assistance program is just one aspect of the state's eviction diversion program, known formally as the Early Resolution Program. Tenants and small landlords can also receive legal aid to help settle eviction cases before they go to trial. Those resources can be found at or by calling (855) 956-5763. The central hub for eviction help in the state is a website called Eviction Help Illinois: There are also separate rental assistance dollars allocated to the Illinois Department of Human Services, with $89.5 million total (including the $50 million court-based program) earmarked to support those efforts this fiscal year, the state said. More information for IDHS housing support programs can be found here: A three-year Chicago pilot program aiding low-income households with legal representation was recently extended through the end of the year thanks to carryover funds from its initial grant (federal stimulus money from the pandemic era) and city dollars, said Michelle Gilbert, legal and policy director for Law Center for Better Housing, one of the organizations involved in the program. The city will need to appropriate more funds in next year's budget (starting Jan. 1, 2026) for the program to continue.
Yahoo
34 minutes ago
- Yahoo
Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed
For Immediate Release Chicago, IL – August 15, 2025 – Today, Zacks Equity Research discusses Envista Holdings NVST, BioLife Solutions BLFS, InfuSystems Holdings INFU and MariMed MRMD. Industry: Medical Products Link: The Zacks Medical - Products industry is likely to remain under pressure through the rest of 2025. While procedural volumes are stable, growth is slowing and high-cost, advanced procedures face adoption and funding hurdles. Capital spending is uneven, with longer sales cycles and reliance on expensive technologies creating risks. Innovation in electrophysiology, structural heart, and AI imaging is struggling to translate into consistent revenues amid regulatory delays, competition and payer scrutiny. Emerging markets face policy headwinds, notably China's margin-eroding volume-based procurement. Tariffs, component shortages, COVID testing declines and product discontinuations are further squeezing margins. Without a clear demand rebound or easing cost pressures, the risks led to continued underperformance for the sector. However, industry participants, such as Envista Holdings, BioLife Solutions, InfuSystems Holdings and MariMed, have adapted to changing consumer preferences, and most of them are witnessing a rise in their share price. These companies also carry a favorable Zacks Rank. Industry Description The industry includes companies that provide medical products and cutting-edge technologies for healthcare services. These companies are primarily focused on research and development and cater to vital therapeutic areas like cardiovascular, nephrology and urology devices. The increase in procedure volumes is driving sales, particularly for surgical products and services. At the same time, cost-cutting measures are helping companies improve their bottom-line performance. However, the industry's profitability picture is under significant strain. Tariff-related expenses are cutting into margins, forcing companies into complex and costly supply-chain restructuring. Persistent component shortages, though less widespread than in prior years, continue to create inefficiencies and constrain output in certain product lines. Additionally, the sharp drop in COVID-relate Major Trends Shaping the Future of the Medical Products Industry AI, Medical Mechatronics & Robotics: The increasing adoption of minimally invasive, robot-assisted surgeries, automated home care, IT-driven patient management, and value-based payment models underscores the rising influence of AI in the Medical Products sector. At the forefront is mechatronics — a fusion of electronics, machine learning, and mechanical engineering — driving innovation across the industry. Companies are making significant progress in AI, robotics, and medical mechatronics, with robotic surgical platforms enabling less invasive procedures and reducing patient trauma. Meanwhile, 3D printing is reshaping the landscape, now used to produce stem cells, blood vessels, heart tissue, prosthetics and skin. These advances highlight the sector's transformative shift toward precision, personalization and improved clinical outcomes. Rising Demand for IVD: The COVID-19 pandemic led to a rise in global demand for diagnostic testing kits to curb the spread of the virus. Testing became a pressing need, leading to a shift in the IVD product pipeline, with many rapid, point-of-care devices entering development. Diagnostic kit manufacturers not only received emergency use authorization from the FDA but also bolstered production to help address testing shortages. Industry players anticipate significant demand for rapid diagnostic testing in the future and are poised to capitalize on this opportunity. Emerging Markets Hold Promise: Driven by growing medical awareness and rising economic prosperity, emerging economies are experiencing strong demand for medical products. Factors such as aging populations, more relaxed regulatory environments, affordable skilled labor, increasing household wealth, and government investment in healthcare infrastructure make these markets highly attractive to global medical device companies. Zacks Industry Rank The Zacks Medical Products industry falls within the broader Zacks Medicalsector. It currently carries a Zacks Industry Rank #149, which places it in the bottom 39% of more than 250 Zacks industries. The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all member stocks, indicates bright near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present a few medical product stocks that you may want to consider for your portfolio, let's take a look at the industry's recent stock-market performance and valuation picture. Industry Performance While the industry has outperformed its own sector, it has underperformed the Zacks S&P 500 composite in the past year. Stocks in this industry have collectively risen 5.1% against the Zacks Medical sector's decline of 19.9%. The S&P 500 has increased 17.2% in the same time frame. Industry's Current Valuation On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 21.4X compared with the S&P 500's 22.9X and the sector's 18.5X. Over the past five years, the industry has traded as high as 27.4X and as low as 17.9X, with the median being at 22X. 4 Promising Medical Product Stocks Envista Holdings enters the second half of 2025 with momentum from a solid first-half performance, supported by diversified growth across equipment, consumables, and specialty products. Continued strength in orthodontics, particularly Brackets & Wires and Spark Clear Aligners, will be augmented by product launches like Spark Retainers, AI-enhanced DTX Studio Clinic and Implant Direct scanning solutions. Penetration into dental service organizations (DSOs) and double-digit growth in emerging markets remain key levers. Operational improvements, including a 15% G&A reduction and manufacturing expansion in Suzhou, China, support margin resilience and local-for-local supply strategies. Pricing actions and cost controls are expected to offset tariff pressures, while acquisitions add incremental growth. Strong demand in infection prevention, diagnostics, and implants should continue, with the third quarter benefiting from Spark Deferral revenue. Stable dental market conditions, coupled with strategic investments in sales, marketing, and R&D, position Envista to deliver on its raised guidance for 2025. For this Brea, CA-based company, the Zacks Consensus Estimate for 2025 revenues is pinned at $2.61 billion. The consensus estimate for earnings is pegged at $1.12 per share. NVST delivered a trailing four-quarter average negative earnings surprise of 16.50%. Presently, the company sports a Zacks Rank #1 (Strong Buy). BioLife Solution is set to benefit from strong demand recovery in cell and gene therapy (CGT) tools, as customer manufacturing activity continues to normalize. The recent integration of Astero, Sexton, and other acquired technologies expands its bioproduction solutions portfolio, allowing deeper penetration into high-growth biopharma segments. Expansion of the cryo-storage services footprint, particularly through the SciSafe network, positions the company to capture more recurring revenues. Efforts to optimize manufacturing capacity and reduce COGS should support margin expansion. New product launches in media and biopreservation, alongside an expanded international sales presence, will help address broader customer needs. Strategic partnerships with therapy developers are expected to drive higher adoption of integrated workflow solutions. While macro uncertainty and biotech funding volatility remain potential headwinds, BioLife's diversified portfolio, operational efficiencies and exposure to commercial-stage CGT programs provide a solid foundation for growth through year-end. For this Bothell, WA-based company, the Zacks Consensus Estimate for 2025 revenues indicates a year-over-year decline of 11.7%. The consensus estimate for earnings indicates growth of 171.4%. It delivered a trailing four-quarter earnings surprise of 123.61%, on average. Presently, the company sports a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here. InfuSystem Holdings' growth trajectory in the second half of 2025 is anchored in its Device Solutions and Patient Services segments. Expansion of oncology and wound care programs, coupled with growing demand for infusion pumps and related disposables, is expected to lift volumes. The company is capitalizing on the broader adoption of negative pressure wound therapy (NPWT) through partnerships with large healthcare providers. A stronger equipment rental base and fleet optimization efforts should further enhance recurring revenue streams. INFU is also investing in service coverage expansion and technology upgrades to improve customer experience and retention. Operational efficiencies from centralized distribution and maintenance hubs are set to reduce turnaround times and lower costs. The integration of new payer contracts and an expanding referral network will support top-line growth. Risks include reimbursement changes and hospital capital spending constraints, but INFU's recurring revenue model and expanding therapeutic reach are positioned to offset these pressures in the near term. Currently, INFU sports a Zacks Rank of 1. For this Rochester Hills, MI-based company, the Zacks Consensus Estimate for 2025 revenues is pegged at $144.2 million. The consensus mark for loss is pinned at 26 cents per share. The company delivered a trailing four-quarter average earnings surprise of 79.17%. MariMed's growth in the remainder of 2025 will be driven by retail expansion, wholesale penetration and new product innovation in the cannabis sector. The opening of new dispensaries in high-traffic markets, along with remodeling existing locations to improve customer flow, is expected to boost sales. The company is scaling cultivation capacity and optimizing yields to meet growing demand while lowering production costs. Expansion of branded product lines, including edibles and wellness offerings, should strengthen shelf presence and margins. Wholesale growth is supported by increasing distribution agreements across multiple states. Investments in automation and processing technology aim to improve consistency and efficiency. Regulatory developments in key states, particularly around adult-use legalization, could provide an upside catalyst. While the industry faces pricing pressure and regulatory uncertainty, MariMed's vertically integrated model, brand strength, and disciplined capital allocation are set to underpin growth in the second half of the year. Currently, MRMD sports a Zacks Rank #1. For this Springfield, MA-based company, the Zacks Consensus Estimate for 2025 loss is pinned at 3 cents per share. The company delivered a trailing four-quarter average earnings surprise of 50.00%. Free: Instant Access to Zacks' Market-Crushing Strategies Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached. Get all the details here >> Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report InfuSystems Holdings, Inc. (INFU) : Free Stock Analysis Report Envista Holdings Corporation (NVST) : Free Stock Analysis Report MariMed Inc. (MRMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
CNBC
an hour ago
- CNBC
Opendoor stock pops 10% as CEO resigns following investor pressure campaign
Opendoor shares popped about 10% on Friday after CEO Carrie Wheeler said she's resigning from the online real estate company, which has seen a surge in recent interest from retail investors. Pressure began building on Wheeler, who took over the top job in 2022, after the company's quarterly earnings report earlier this month failed to reassure investors that a turnaround is underway. The stock is up more than sixfold since bottoming out at 51 cents in June, a price that put the company at risk of being delisted from the Nasdaq. "The last weeks of intense outside interest in Opendoor have come at a time when the company needs to stay focused and charging ahead," Wheeler wrote in a post on X. "I believe the best thing I can do for Opendoor now is to accelerate my succession plans that I shared with the Board mid-year and make room for new leadership to take the reins." Opendoor's business involves using technology to buy and sell homes, pocketing the gains. In its latest earnings report, Opendoor said it expects to acquire just 1,200 homes in the third quarter, down from 1,757 in the second quarter and 3,504 in the third quarter of 2024. It's also pulling down marketing spending. Hedge fund manager Eric Jackson, who spearheaded Opendoor's stock jump in July, celebrated the news and told his new band of followers on X, "Let's start THINKING BIG AGAIN." Jackson said last month on X that his firm had taken a stake in the company and was betting it would be a "100-bagger over the next few years." Jackson has been a loud voice on X pushing for Wheeler's departure, and was recently joined by Opendoor co-founder and venture capitalist Keith Rabois, who posted on Aug. 13 that "not a single founder nor executive" who guided the company to its IPO supports Wheeler as CEO. Opendoor on Friday named technology chief Shrisha Radhakrishna as "president and interim leader" and said a CEO search is underway. Opendoor went public through a special purpose acquisition company in 2020, riding a SPAC wave supported by low interest rates and Covid-era market euphoria. The soaring inflation and rising interest rates that followed hit all of technology stocks, but had an outsized impact on Opendoor due it its direct exposure to mortgage rates. The company lost 99% of its value from early 2021 through its trough in June. With Friday's gains, its market cap stands at about $2.5 billion.
